Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia

Most acute myeloid leukemia (AML) cells are argininosuccinate synthetase‐deficient. Pegylated arginine deiminase (ADI‐PEG20) monotherapy depletes circulating arginine, thereby selectively inducing tumor cell death. ADI‐PEG20 was shown to induce complete responses in ~10% of relapsed/refractory or po...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Med
Main Authors: Tsai, Hui‐Jen, Hsiao, Hui‐Hua, Hsu, Ya‐Ting, Liu, Yi‐Chang, Kao, Hsiao‐Wen, Liu, Ta‐Chih, Cho, Shih‐Feng, Feng, Xiaoxing, Johnston, Amanda, Bomalaski, John S., Kuo, Ming‐Chung, Chen, Tsai‐Yun
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2021
Assuntos:
Clinical Cancer Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085967/
https://ncbi.nlm.nih.gov/pubmed/33787078
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3871
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados